IMMUNE DEFENCE
Key enzyme TPL-2 helps immune cells kill disease-causing bacteria
A new study sheds light on how the body’s response to bacterial infection is controlled in a key type of immune cell – the macrophage.
Stories written by Genevieve Timmins
CANCER CLUES
New study reveals weak spots in chemotherapy-resistant cancer cells
Molecular ‘weak spots' in cancer cells recovering from chemotherapy could provide the basis for better treatments, according to new research
GLOBAL HEALTH BIOSENSORS
Low-cost, disease-detecting biosensors show global health promise
Researchers have developed low-cost, biodegradable biosensors for global health applications in resource-limited settings.
COVID DIALYSIS STUDY
New study to explore how well COVID-19 vaccines protect dialysis patients
A new study will assess how well COVID-19 vaccines work in people who attend hospital for their dialysis treatment (haemodialysis).
CHAMPIONING CHILD HEALTH
New Centre for Paediatrics and Child Health launches at Imperial
A major new centre has launched to bring together paediatric research, education and training across Imperial and West London.
1
COVID IMMUNITY
COVID-19 immunity lasts over 4 months, but antibody and T cells can “uncouple"
Majority carry neutralizing antibodies 16-18 weeks after mild or asymptomatic SARS-CoV-2 infection, but antibody and T cell responses can "uncouple".
2
Audio
Glisten up
Podcast: Child health, Bionic Olympics, and a better Christmas dinner
In this edition: A new child health centre opens, assistive technologies at the Cybathlon, and healthier Christmas food for you and the planet.
CANCER TRIAL
Imperial set to lead UK trial of innovative new cancer drug
The trial will assess a promising new drug developed by Imperial scientists, designed to treat multiple myeloma and diffuse large b-cell lymphoma.
2
Under the microscope
Molecular insights into key drug target could help to enhance cancer treatments
New research reveals how a key protein in cells could be tweaked to make cancer treatments more effective.
TRIPLE THREAT
New anti-cancer drug combo treatment shows promise for myeloma patients
Phase 3 trial results reveal that selinexor – a relatively new anti-cancer drug – improves patient outcomes when combined with established treatments.
